Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Exploring the Role of Molnupiravir in Clinical Trials for COVID-19 Treatment

1 / 1
trials open to patients / all trials
8+
Countries

About the substance

Table of Contents

What is Molnupiravir?

Molnupiravir is an oral antiviral medication that was developed to treat COVID-19. It is also known by several other names, including MK-4482, EIDD-2801, and is marketed under the brand name Lagevrio[1]. This medication was developed by Merck Sharp & Dohme (MSD) and received emergency use authorization from regulatory authorities in various countries for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease[2].

How Does Molnupiravir Work?

Molnupiravir works through a mechanism known as "viral error catastrophe" or "lethal mutagenesis." When taken orally, molnupiravir is absorbed into the bloodstream and is converted in the body to its active form called N-hydroxycytidine (NHC)[3].

The active form of molnupiravir (NHC) then distributes into cells where it is phosphorylated to form the pharmacologically active NHC-triphosphate (NHC-TP). When the virus attempts to replicate its genetic material, this active compound is incorporated into the viral RNA by the viral RNA polymerase. The incorporation of NHC causes errors in the viral genetic code, resulting in an accumulation of mutations that prevent the virus from reproducing properly[4]. This process essentially forces the virus to mutate itself out of existence, leading to inhibition of viral replication.

This mechanism differs from many other antiviral drugs that typically block specific viral enzymes or prevent the virus from entering cells.

Medical Uses

COVID-19 Treatment

Molnupiravir is primarily indicated for the treatment of mild to moderate COVID-19 in adults who have tested positive for SARS-CoV-2 and who are at high risk for progression to severe COVID-19, including hospitalization or death. It is designed to be used early in the course of infection, ideally within 5 days of symptom onset[5].

High-risk individuals who may benefit from molnupiravir treatment include those who are:

  • Over 60 years of age
  • Have underlying health conditions such as:
    • Cardiovascular disease
    • Diabetes
    • Chronic respiratory disease
    • Obesity
    • Compromised immune systems
    • Cancer
    • Chronic kidney disease[6]

Dosage and Administration

The standard recommended dosage of molnupiravir for COVID-19 treatment is:

  • 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days (a total of 10 doses)
  • Treatment should be initiated as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset[7]

The capsules should be swallowed whole and can be taken with or without food. If a dose is missed, it should be taken as soon as possible if it's within 10 hours of the scheduled time. If more than 10 hours have passed, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended[8].

Efficacy in COVID-19 Treatment

Clinical trials have assessed the efficacy of molnupiravir in treating COVID-19. The most notable study was the MOVe-OUT trial, which showed that molnupiravir reduced the risk of hospitalization or death in unvaccinated adults with mild-to-moderate COVID-19 who were at high risk for severe disease.

Key findings from clinical trials include:

  • A reduction of approximately 30% in the risk of hospitalization or death compared to placebo when treatment was initiated within 5 days of symptom onset[9]
  • Faster time to negative SARS-CoV-2 viral test results compared to placebo
  • Reduced duration and severity of COVID-19 symptoms[10]

It's important to note that molnupiravir's effectiveness appears to be lower than some other COVID-19 treatments like nirmatrelvir/ritonavir (Paxlovid), which has shown a reduction of up to 89% in the risk of hospitalization and death[11].

The PLATCOV platform trial found that molnupiravir accelerated viral clearance in patients with early symptomatic COVID-19, though its arm was eventually closed after meeting pre-defined stopping criteria[12].

Possible Side Effects

Molnupiravir is generally well-tolerated, but like all medications, it can cause side effects. Clinical trials have identified several potential adverse reactions:

Common side effects (affecting up to 1 in 10 people):

  • Diarrhea
  • Nausea
  • Dizziness
  • Headache[13]

Less common side effects:

  • Allergic reactions
  • Altered taste
  • Fatigue
  • Vomiting[14]

Laboratory abnormalities observed in some patients include:

  • Decreased white blood cell counts
  • Increased liver enzymes
  • Altered blood chemistry values[15]

Special Populations

Pregnancy and Breastfeeding

Molnupiravir is not recommended for use during pregnancy due to potential fetal harm based on animal reproduction studies. There is a pregnancy surveillance program for women who receive molnupiravir during pregnancy[16].

Women of childbearing potential should use effective contraception during treatment and for 4 days after the last dose. Men who are sexually active with women of childbearing potential should use reliable contraception during treatment and for at least 3 months after the final dose[17].

It is not known whether molnupiravir or its metabolites are present in breast milk. The effects on breastfed infants or milk production have not been studied, so caution is advised for nursing mothers.

Renal and Hepatic Impairment

Studies have examined the pharmacokinetics of molnupiravir in patients with renal and hepatic impairment:

  • For patients with severe renal impairment, research suggests that the plasma pharmacokinetics of NHC (the active metabolite) is similar to that observed in patients with normal renal function, indicating that no dosage adjustment is required[18].

  • Similarly, for patients with moderate hepatic impairment, studies indicate that no dosage adjustment is necessary as the pharmacokinetics of NHC is not significantly altered[19].

Drug Interactions

One of the advantages of molnupiravir is its relatively low potential for drug interactions compared to some other COVID-19 treatments. Molnupiravir is not metabolized by cytochrome P450 enzymes, which are involved in the metabolism of many medications, reducing the likelihood of significant drug-drug interactions[20].

Clinical studies have investigated potential interactions with other medications, including:

  • The combination of molnupiravir and Paxlovid (nirmatrelvir/ritonavir)
  • Other antiviral medications

These studies generally indicate minimal clinically significant interactions, making molnupiravir suitable for patients on multiple medications[21]. However, as with any medication, patients should inform their healthcare provider about all other medications they are taking.

Other Potential Uses

Influenza Treatment

Research is exploring molnupiravir's potential effectiveness against other viral infections, particularly influenza. A Phase 2a clinical trial (MK-4482-017) is evaluating the efficacy and safety of molnupiravir in healthy participants inoculated with experimental influenza virus[22].

The study is testing whether molnupiravir can:

  • Reduce peak viral load compared to placebo when initiated 12 hours after inoculation
  • Reduce viral load area under the curve compared to placebo when initiated 2 days after inoculation

Respiratory Syncytial Virus (RSV)

Molnupiravir is also being studied for its potential effectiveness against RSV. The AD ASTRA trial is assessing the antiviral effects of various interventions, including molnupiravir, in patients with early symptomatic RSV infection[23].

Additionally, a Phase 2a trial (MK-4482-017) is evaluating molnupiravir's efficacy and safety in healthy participants inoculated with experimental RSV[24].

Dengue Fever

The ADAPT (Adaptive Dengue Antiviral Platform Trial) is investigating molnupiravir's potential antiviral effectiveness in early dengue virus infection[25]. This trial aims to determine if molnupiravir can help clear the dengue virus more quickly and reduce the severity of symptoms.

Limitations and Considerations

While molnupiravir represents an important addition to COVID-19 treatment options, there are several important limitations and considerations:

  1. Timing: Molnupiravir is most effective when started early in the course of infection, ideally within 5 days of symptom onset.

  2. Resistance concerns: Due to its mechanism of action (inducing mutations), there are theoretical concerns about the potential for emergence of new viral variants. Ongoing surveillance is important to monitor for this possibility[26].

  3. Comparative efficacy: Other treatments like Paxlovid (nirmatrelvir/ritonavir) have shown higher efficacy rates in reducing hospitalization and death in high-risk COVID-19 patients.

  4. Pregnancy restrictions: The contraindications for use during pregnancy limit its application in this population.

  5. Vaccination importance: Molnupiravir is not a substitute for vaccination. COVID-19 vaccines remain the most important tool for preventing severe disease.

Conclusion

Molnupiravir represents an important oral antiviral option for treating COVID-19, particularly for high-risk patients who cannot take other treatments due to contraindications or drug interactions. Its mechanism of action through viral error catastrophe provides a unique approach to fighting viral infections.

While it has shown efficacy in reducing hospitalization and death from COVID-19, its effectiveness appears somewhat lower than some alternative treatments. Its favorable drug interaction profile and ease of oral administration make it a valuable option in certain clinical scenarios.

Research continues to explore molnupiravir's potential application against other viral infections, including influenza, RSV, and dengue fever, which may expand its therapeutic utility in the future.

As with any medication, patients should discuss the potential benefits and risks with their healthcare provider to determine if molnupiravir is appropriate for their specific situation.

References

  1. NCT06615869. clinicaltrials.gov.
  2. NCT05595824. clinicaltrials.gov.
  3. NCT05386589. clinicaltrials.gov.
  4. NCT06223932. clinicaltrials.gov.
  5. NCT04575597. clinicaltrials.gov.
  6. NCT05459532. clinicaltrials.gov.
  7. NCT05412173. clinicaltrials.gov.
  8. NCT05386758. clinicaltrials.gov.
  9. NCT06667700. clinicaltrials.gov.
  10. NCT04405570. clinicaltrials.gov.
  11. NCT05894603. clinicaltrials.gov.
  12. NCT05041907. clinicaltrials.gov.
  13. NCT04939428. clinicaltrials.gov.
  14. NCT04575584. clinicaltrials.gov.
  15. NCT05559905. clinicaltrials.gov.
  16. NCT05195060. clinicaltrials.gov.
  17. NCT05818124. clinicaltrials.gov.
  18. NCT05386758. clinicaltrials.gov.
  19. NCT05386589. clinicaltrials.gov.
  20. NCT05412173. clinicaltrials.gov.
  21. NCT04746183. clinicaltrials.gov.
  22. NCT05818124. clinicaltrials.gov.
  23. NCT05648448. clinicaltrials.gov.
  24. NCT05559905. clinicaltrials.gov.
  25. NCT06551844. clinicaltrials.gov.
  26. NCT06223932. clinicaltrials.gov.

Conditions where MOLNUPIRAVIR is being studied

Each condition opens its own overview and trial list

COVID-19

Trials with MOLNUPIRAVIR

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.